Pharmacist to the Rescue: Overcoming Obstacles for Select Patients

doi:10.5863/1551-6776-27.5.407

Editorial

. 2022;27(5):407-408.

doi: 10.5863/1551-6776-27.5.407. Epub 2022 Jul 6.

Pharmacist to the Rescue: Overcoming Obstacles for Select Patients

Elizabeth Autry¹, Robert Kuhn¹

Affiliations

Affiliation

¹ Department of Pharmacy, University of Kentucky Healthcare, Lexington, KY, USA and the Department of Pharmacy Practice and Science, College of Pharmacy (EA, RK), University of Kentucky. Lexington, KY USA.

PMID: 35845564
PMCID: PMC9268107
DOI: 10.5863/1551-6776-27.5.407

Editorial

Pharmacist to the Rescue: Overcoming Obstacles for Select Patients

Elizabeth Autry et al. J Pediatr Pharmacol Ther. 2022.

. 2022;27(5):407-408.

doi: 10.5863/1551-6776-27.5.407. Epub 2022 Jul 6.

Authors

Elizabeth Autry¹, Robert Kuhn¹

Affiliation

¹ Department of Pharmacy, University of Kentucky Healthcare, Lexington, KY, USA and the Department of Pharmacy Practice and Science, College of Pharmacy (EA, RK), University of Kentucky. Lexington, KY USA.

PMID: 35845564
PMCID: PMC9268107
DOI: 10.5863/1551-6776-27.5.407

No abstract available

Keywords: CFTR modulators; Cystic fibrosis; desensitization; elexacaftor/tezacaftor/ivacaftor.

PubMed Disclaimer

Conflict of interest statement

Disclosure. The authors declare no conflicts or financial interest in any product or service mentioned in this manuscript. Drs. Kuhn and Autry have received financial support for clinical research from Vertex Pharmaceuticals

Similar articles

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW, Murphy J, Sinha IP, Nevitt SJ. Southern KW, et al. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2023 Nov 20;11:CD010966. doi: 10.1002/14651858.CD010966.pub4. PMID: 33331662 Free PMC article. Updated.
The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L, Favia M, Di Gioia S, Laselva O, Bisogno A, Casavola V, Colombo C, Conese M. Guerra L, et al. Expert Opin Drug Discov. 2020 Aug;15(8):873-891. doi: 10.1080/17460441.2020.1750592. Epub 2020 Apr 15. Expert Opin Drug Discov. 2020. PMID: 32290721 Review.

See all similar articles

References

1. Middleton PG, Mall MA, Previnek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New Engl J Med . 2019;381:1809–1819. - PMC - PubMed
1. Patterson A, Autry E, Kuhn R, Wurth M. Ivacaftor Drug Desensitization. Pediatr Pulmonol . 2019;54(6):672–674. - PubMed
1. Diseroad ER, Mogayzel PJ, Pan A. Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor. J Pediatr Pharmacol Ther . 2022;27(5):463–466. - PMC - PubMed
1. Loyd I, Papac N, Hirshburg J, Levin J, Dannelley et al. If at first you don't succeed, Triafta again. J Pediatr Pharmacol Ther . 2022;27(5):467–469. - PMC - PubMed
1. Green G, Berg C, Polli J et al. Pharmacopeial Standards for Subdivision of Characteristics of Scored Tablets. Pharmacopeial Form . 2009;35(6):1592–1612.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

[1] Middleton PG, Mall MA, Previnek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New Engl J Med . 2019;381:1809–1819. - PMC - PubMed

[2] Middleton PG, Mall MA, Previnek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New Engl J Med . 2019;381:1809–1819. - PMC - PubMed

[3] Patterson A, Autry E, Kuhn R, Wurth M. Ivacaftor Drug Desensitization. Pediatr Pulmonol . 2019;54(6):672–674. - PubMed

[4] Patterson A, Autry E, Kuhn R, Wurth M. Ivacaftor Drug Desensitization. Pediatr Pulmonol . 2019;54(6):672–674. - PubMed

[5] Diseroad ER, Mogayzel PJ, Pan A. Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor. J Pediatr Pharmacol Ther . 2022;27(5):463–466. - PMC - PubMed

[6] Diseroad ER, Mogayzel PJ, Pan A. Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor. J Pediatr Pharmacol Ther . 2022;27(5):463–466. - PMC - PubMed

[7] Loyd I, Papac N, Hirshburg J, Levin J, Dannelley et al. If at first you don't succeed, Triafta again. J Pediatr Pharmacol Ther . 2022;27(5):467–469. - PMC - PubMed

[8] Loyd I, Papac N, Hirshburg J, Levin J, Dannelley et al. If at first you don't succeed, Triafta again. J Pediatr Pharmacol Ther . 2022;27(5):467–469. - PMC - PubMed

[9] Green G, Berg C, Polli J et al. Pharmacopeial Standards for Subdivision of Characteristics of Scored Tablets. Pharmacopeial Form . 2009;35(6):1592–1612.

[10] Green G, Berg C, Polli J et al. Pharmacopeial Standards for Subdivision of Characteristics of Scored Tablets. Pharmacopeial Form . 2009;35(6):1592–1612.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pharmacist to the Rescue: Overcoming Obstacles for Select Patients

Affiliation

Pharmacist to the Rescue: Overcoming Obstacles for Select Patients

Authors

Affiliation

Conflict of interest statement

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources